Is Drägerwerk KGaA (XTRA:DRW3) Undervalued As Q2 Earnings Lift Sales And Net Income?

Why Drägerwerk KGaA Stock Is In Focus After Q2 Earnings

Drägerwerk KGaA (XTRA:DRW3) is back on investor radar after its second quarter 2026 earnings, with sales of €847.31 million and net income of €29.52 million reported for the period.

For the first six months to June 30, 2026, Drägerwerk KGaA reported sales of €1,603.18 million and net income of €40.95 million, compared with the same metrics a year earlier.

See our latest analysis for Drägerwerk KGaA.

The Q2 update has arrived after a strong run for Drägerwerk KGaA, with a 30 day share price return of 33.41% and a year to date share price return of 63.45%. Over a longer horizon, the 1 year total shareholder return of 73.79% and 3 year total shareholder return of 166.32% indicate that recent momentum builds on a much stronger period for investors.

If this kind of earnings driven move has your attention, it could be a good moment to see what else is moving and scan 105 top founder-led companies

Bulls see Drägerwerk KGaA’s rising earnings and strong share price run as the start of a reset. Bears worry the move already prices in the good news. Do the current numbers still leave room in the valuation?

Price to Earnings Of 12.2x For Drägerwerk KGaA: Is It Justified?

On the latest figures, Drägerwerk KGaA trades on a P/E of 12.2x, which sits well below several reference points and has caught the attention of value focused investors.

The P/E ratio compares the current share price with earnings per share. For a company like Drägerwerk KGaA, which operates in medical and safety technology with a history of positive earnings, P/E is a common shorthand for how much investors are willing to pay for each euro of profit.

According to the data, DRW3 is described as trading at good value compared with peers and the wider industry. The P/E of 12.2x is set against a peer average of 25.2x and a European Medical Equipment industry average of 26.5x. This points to a sizeable valuation gap. The same framework suggests an estimated fair P/E of 17.1x, which is higher than the current multiple and indicates a level the market could potentially move towards if sentiment and assumptions align with that fair ratio view.

For investors who want to see how this fair ratio is calculated and stress tested across different assumptions, it is worth taking a closer look at the detailed work behind it. Explore the SWS fair ratio for Drägerwerk KGaA

Result: Price-to-Earnings of 12.2x (UNDERVALUED)

However, investors in Drägerwerk KGaA still face the risk that the recent share price surge, the current premium to analyst targets, and execution across diverse global markets could all shift sentiment quickly.

Find out about the key risks to this Drägerwerk KGaA narrative.

Another View On Drägerwerk KGaA’s Value

The SWS DCF model takes a different angle on Drägerwerk KGaA. It suggests the stock at €111.80 trades below an estimated future cash flow value of €254.86. That points to a large implied discount. If both earnings multiples and cash flows indicate a low valuation, what might the market be missing?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Drägerwerk KGaA for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 262 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both risks and rewards in the picture for Drägerwerk KGaA, it makes sense to move quickly, review the data yourself, and decide where you stand. To see the balance of potential upside and downside in one place, take a closer look at the 4 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Drägerwerk KGaA?

If Drägerwerk KGaA has sharpened your focus, use this momentum to review fresh stock ideas that match your own risk tolerance, income goals, and quality filters.

• Target potential mispricings and cast a wider net across quality companies by running the 262 high quality undervalued stocks.
• Strengthen your income stream with companies that prioritize reliable payouts by checking the 440 dividend fortresses.
• Prioritize resilience and steadier compounding potential by filtering for 296 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com